These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 16049637)

  • 21. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
    Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
    Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of therapeutic response to donepezil by positron emission tomography.
    Shimada A; Hashimoto H; Kawabe J; Higashiyama S; Kai T; Kataoka K; Tagawa R; Kawarada Y; Nakanishi A; Inoue K; Shiomi S; Kiriike N
    Osaka City Med J; 2011 Jun; 57(1):11-9. PubMed ID: 22106763
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.
    Articus K; Baier M; Tracik F; Kühn F; Preuss UW; Kurz A
    Int J Clin Pract; 2011 Jul; 65(7):790-6. PubMed ID: 21645184
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rivastigmine in Alzheimer disease: efficacy over two years.
    Grossberg G; Irwin P; Satlin A; Mesenbrink P; Spiegel R
    Am J Geriatr Psychiatry; 2004; 12(4):420-31. PubMed ID: 15249280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study.
    Gauthier S; Juby A; Morelli L; Rehel B; Schecter R;
    Curr Med Res Opin; 2006 Nov; 22(11):2251-65. PubMed ID: 17076986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study.
    Drzezga A; Lautenschlager N; Siebner H; Riemenschneider M; Willoch F; Minoshima S; Schwaiger M; Kurz A
    Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1104-13. PubMed ID: 12764551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relatively preserved hippocampal glucose metabolism in mild Alzheimer's disease.
    Ishii K; Sasaki M; Yamaji S; Sakamoto S; Kitagaki H; Mori E
    Dement Geriatr Cogn Disord; 1998; 9(6):317-22. PubMed ID: 9769444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
    López-Pousa S; Turon-Estrada A; Garre-Olmo J; Pericot-Nierga I; Lozano-Gallego M; Vilalta-Franch M; Hernández-Ferràndiz M; Morante-Muñoz V; Isern-Vila A; Gelada-Batlle E; Majó-Llopart J
    Dement Geriatr Cogn Disord; 2005; 19(4):189-95. PubMed ID: 15677866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.
    Feldman HH; Ferris S; Winblad B; Sfikas N; Mancione L; He Y; Tekin S; Burns A; Cummings J; del Ser T; Inzitari D; Orgogozo JM; Sauer H; Scheltens P; Scarpini E; Herrmann N; Farlow M; Potkin S; Charles HC; Fox NC; Lane R
    Lancet Neurol; 2007 Jun; 6(6):501-12. PubMed ID: 17509485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rivastigmine in vascular dementia.
    Vincent S; Lane R
    Int Psychogeriatr; 2003; 15 Suppl 1():201-5. PubMed ID: 16191241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease.
    Grossberg GT; Olin JT; Somogyi M; Meng X
    Int J Clin Pract; 2011 Apr; 65(4):465-71. PubMed ID: 21309961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of long-term treatment effect of rivastigmine in Alzheimer's disease: a role for beta-amyloid plasma levels?
    Sobów T; Kłoszewska I; Flirski M; Liberski P
    Neurol Neurochir Pol; 2009; 43(6):507-16. PubMed ID: 20054753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease.
    Karaman Y; Erdoğan F; Köseoğlu E; Turan T; Ersoy AO
    Dement Geriatr Cogn Disord; 2005; 19(1):51-6. PubMed ID: 15383747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic correlates of executive dysfunction. Different patterns in mild and very mild Alzheimer's disease.
    Bracco L; Bessi V; Piccini C; Mosconi L; Pupi A; Sorbi S
    J Neurol; 2007 Aug; 254(8):1052-65. PubMed ID: 17385079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bihemispheric cerebral FDG PET correlates of cognitive dysfunction as assessed by the CERAD in Alzheimer's disease.
    Schönknecht OD; Hunt A; Toro P; Guenther T; Henze M; Haberkorn U; Schröder J
    Clin EEG Neurosci; 2011 Apr; 42(2):71-6. PubMed ID: 21675596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of treatment response to rivastigmine in Alzheimer's dementia.
    Adler G; Brassen S; Chwalek K; Dieter B; Teufel M
    J Neurol Neurosurg Psychiatry; 2004 Feb; 75(2):292-4. PubMed ID: 14742608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
    Tosun D; Schuff N; Jagust W; Weiner MW;
    Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of standardized uptake value to assess cerebral glucose metabolism.
    Yamaji S; Ishii K; Sasaki M; Mori T; Kitagaki H; Sakamoto S; Mori E
    Clin Nucl Med; 2000 Jan; 25(1):11-6. PubMed ID: 10634523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.
    Mosconi L
    Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):486-510. PubMed ID: 15747152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psychosis in Alzheimer's disease is associated with frontal metabolic impairment and accelerated decline in working memory: findings from the Alzheimer's Disease Neuroimaging Initiative.
    Koppel J; Sunday S; Goldberg TE; Davies P; Christen E; Greenwald BS;
    Am J Geriatr Psychiatry; 2014 Jul; 22(7):698-707. PubMed ID: 23672944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.